Skip to main content

Table 2 Patient Therapy (n = 236)

From: Insulin-like growth factor receptor and sphingosine kinase are prognostic and therapeutic targets in breast cancer

Therapy n (%)
Anti-Endocrine Therapy = 165 (69.9)
 Tamoxifen 75 (31.7)
 Anastrozole (Arimidex) 45 (19)
 Exemestane (Aromasin) 8 (3.3)
 Letrozole (Femara) 32 (13.5)
 Goserelin (Zoladex) 4 (1.6)
 Aromatase Inhibitors 1 (0.4)
HER2 Therapy = 67 (28.4)
 Trastuzumab (Herceptin) 66 (27.9)
 Lapatinib (Tyverb) 1 (0.4)
Chemotherapy 194 (82.2)
 AC: Adriamycin (Doxorubicin), Cyclophosphamide 49 (20.7)
 Anthracycline 1 (0.4)
 Docetaxel (Taxotere) 19 (8.0)
 TAC: Docetaxel (Taxotere), Adriamycin (Doxorubicin) and Cyclophosphamide 22 (9.3)
 TC: Docetaxel (Taxotere) and Cyclophosphamide 1 (0.4)
 TCH: Docetaxel (Taxotere), Carboplatin and Trastuzumab 9 (3.8)
 EC: Epirubicin and Cyclophosphamide 3 (1.2)
 FEC: 5-Fluorouracil, Epirubicin and Cyclophosphamide 45 (19.0)
 Paclitaxel (Taxol)/Taxane 36 (15.2)
 FAC (or CAF): 5-Fluorouracil, Doxorubicin and Cyclophosphamide 4 (1.6)
 Capecitabine (Xeloda) 3 (1.2)
 5-Fluorouracil 1 (0.4)
 Carboplatin 1 (0.4)
Unknown 46 (19.4)